Immunosurveillance in clinical cancer management.
Kroemer G, Chan TA, Eggermont AMM, Galluzzi L.
CA Cancer J Clin. 2024 Mar-Apr;74(2):187-202. doi: 10.3322/caac.21818. Epub 2023 Oct 25.
Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.
Chaft JE, Shyr Y, Sepesi B, Forde PM.
J Clin Oncol. 2022 Feb 20;40(6):546-555. doi: 10.1200/JCO.21.01589. Epub 2022 Jan 5.
Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment.
Chu X, Mi B, Xiong Y, Wang R, Liu T, Hu L, Yan C, Zeng R, Lin J, Fu H, Liu G, Zhang K, Bian L.
Biomaterials. 2025 Jan;312:122714. doi: 10.1016/j.biomaterials.2024.122714. Epub 2024 Jul 27.
Association of Neoadjuvant Immunotherapy With Postoperative Major Morbidity After Oncologic Surgery.
Habib DRS, Shou M, Philips RH, Pickens A, Hawkins AT, Idrees K, Khan A.
Ann Surg Oncol. 2024 Dec;31(13):8508-8513. doi: 10.1245/s10434-024-16284-8. Epub 2024 Sep 28.
Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China.
Zhang Q, Zhang T, Gu J, Zhang X, Mao Y, Zhu Y, Zhang J, Wang J, Chen S, Cao Y, Wang M, Wang C.
Front Immunol. 2025 Feb 24;16:1548520. doi: 10.3389/fimmu.2025.1548520. eCollection 2025.
A meta-analysis of adoptive immunotherapy in postoperative hepatocellular carcinoma.
Zhao H, Zheng M, Wang K, Wang L, He H, Wang M, Shi Y, Huang S, Ji F, Li X, Zhu H, Wang L, Zhang X, Shi X, Zhao S, Fu B, Wu T.
J Cancer Res Ther. 2018;14(4):807-814. doi: 10.4103/jcrt.JCRT_858_17.
Impact of neoadjuvant immunotherapy on postoperative complications after surgery for rectal cancer.
Shou M, Habib DRS, Idrees K, Hawkins A, Ford M, Lee H, Khan B, Khan A.
J Surg Oncol. 2024 Aug;130(2):322-328. doi: 10.1002/jso.27694. Epub 2024 May 27.
Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy.
Bai G, Chen X, Peng Y, Ji Y, Bie F, Liu Y, Yang Z, Gao S.
Thorac Cancer. 2024 May;15(14):1138-1148. doi: 10.1111/1759-7714.15297. Epub 2024 Apr 4.
Salvage immunotherapy of malignant glioma.
Ingram M, Jacques S, Freshwater DB, Techy GB, Shelden CH, Helsper JT.
Arch Surg. 1987 Dec;122(12):1483-6. doi: 10.1001/archsurg.1987.01400240131025.
Comparative review of KEYNOTE-689 and NIVOPOSTOP trials and their impact on perioperative immunotherapy in locally advanced head and neck cancer.
Imamura Y, Kanno M, Fujieda S.
Cancer Treat Rev. 2025 Nov;140:103018. doi: 10.1016/j.ctrv.2025.103018. Epub 2025 Aug 27.
